The objective underlying cancer immunotherapies targeting the PD-1/PD-L1 signaling nexus transcends mere enhancement of immune cell function within the tumor microenvironment; rather, it aims to restore immune system equilibrium [21]. Here, PDCD1 is linked to neoplasm.